156 related articles for article (PubMed ID: 7537482)
1. The effect of combined intravenous and oral clodronate treatment on bone pain in patients with metastatic prostate cancer.
Kylmälä T; Tammela TL; Lindholm TS; Seppänen J
Ann Chir Gynaecol; 1994; 83(4):316-9. PubMed ID: 7537482
[TBL] [Abstract][Full Text] [Related]
2. The use of bisphosphonate for the palliative treatment of painful bone metastasis due to hormone refractory prostate cancer.
Heidenreich A; Hofmann R; Engelmann UH
J Urol; 2001 Jan; 165(1):136-40. PubMed ID: 11125382
[TBL] [Abstract][Full Text] [Related]
3. The use of bone markers in a 6-week study to assess the efficacy of oral clodronate in patients with metastatic bone disease.
Brown JE; McCloskey EV; Dewar JA; Body JJ; Cameron DA; Harnett AN; Ruutu M; Purohit OP; Tähtelä R; Coleman RE
Calcif Tissue Int; 2007 Nov; 81(5):341-51. PubMed ID: 17874331
[TBL] [Abstract][Full Text] [Related]
4. Use of bisphosphonates can dramatically improve pain in advanced hormone-refractory prostate cancer patients.
Rodrigues P; Hering F; Campagnari JC
Prostate Cancer Prostatic Dis; 2004; 7(4):350-4. PubMed ID: 15534620
[TBL] [Abstract][Full Text] [Related]
5. [Clodronate in the palliative therapy of bone-metastasized prostatic carcinoma].
Vorreuther R; Klotz T; Engelking R
Urologe A; 1992 Mar; 31(2):63-6. PubMed ID: 1373255
[TBL] [Abstract][Full Text] [Related]
6. Disodium clodronate in the treatment of pain due to bone metastases.
Luzzani M; Vidili MG; Rissotto R; Nobile MT; Beghè F; Rosso R; Gottlieb A
Int J Clin Pharmacol Res; 1990; 10(4):243-6. PubMed ID: 2150406
[TBL] [Abstract][Full Text] [Related]
7. Bisphosphonates for cancer patients: why, how, and when?
Body JJ; Mancini I
Support Care Cancer; 2002 Jul; 10(5):399-407. PubMed ID: 12136223
[TBL] [Abstract][Full Text] [Related]
8. [Randomized trial of two administration schedule of bonephos (Clodronate) in patients with painful bone metastasis].
Moiseenko VM; Blinov NN; Semiglazov VV; Konstantinova MM; Trishkina EA
Vopr Onkol; 1998; 44(6):725-8. PubMed ID: 10087976
[TBL] [Abstract][Full Text] [Related]
9. Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain.
Ernst DS; Tannock IF; Winquist EW; Venner PM; Reyno L; Moore MJ; Chi K; Ding K; Elliott C; Parulekar W
J Clin Oncol; 2003 Sep; 21(17):3335-42. PubMed ID: 12947070
[TBL] [Abstract][Full Text] [Related]
10. [The effects of clodronate for the pain treatment of bone metastasis due to prostate cancer].
Ozyuvaci E; Altan A; Demir C
Agri; 2005 Jan; 17(1):49-53. PubMed ID: 15791501
[TBL] [Abstract][Full Text] [Related]
11. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer.
Small EJ; Smith MR; Seaman JJ; Petrone S; Kowalski MO
J Clin Oncol; 2003 Dec; 21(23):4277-84. PubMed ID: 14581438
[TBL] [Abstract][Full Text] [Related]
12. [Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases].
Tubiana-Hulin M; Beuzeboc P; Mauriac L; Barbet N; Frenay M; Monnier A; Pion JM; Switsers O; Misset JL; Assadourian S; Bessa E
Bull Cancer; 2001 Jul; 88(7):701-7. PubMed ID: 11495824
[TBL] [Abstract][Full Text] [Related]
13. The analgesic efficacy of clodronate compared with placebo in patients with painful bone metastases from prostatic cancer.
Strang P; Nilsson S; Brändstedt S; Sehlin J; Borghede G; Varenhorst E; Bandman U; Borck L; Englund G; Selin L
Anticancer Res; 1997; 17(6D):4717-21. PubMed ID: 9494595
[TBL] [Abstract][Full Text] [Related]
14. A double blind randomized study of oral clodronate in the treatment of bone metastases from tumors poorly responsive to chemotherapy.
Piga A; Bracci R; Ferretti B; Sandri P; Nortilli R; Acito L; Pancotti A; Di Furia L; Carle F; Cellerino R
J Exp Clin Cancer Res; 1998 Jun; 17(2):213-7. PubMed ID: 9700583
[TBL] [Abstract][Full Text] [Related]
15. [186Re]HEDP in the palliation of painful bone metastases from cancers other than prostate and breast.
Minutoli F; Herberg A; Spadaro P; Restifo Pecorella G; Baldari S; Aricò D; Altavilla G; Baldari S
Q J Nucl Med Mol Imaging; 2006 Dec; 50(4):355-62. PubMed ID: 17043634
[TBL] [Abstract][Full Text] [Related]
16. Clinical trials in metastatic breast cancer to bone: past--present--future.
Body JJ
Can J Oncol; 1995 Dec; 5 Suppl 1():16-27. PubMed ID: 8853520
[TBL] [Abstract][Full Text] [Related]
17. Effects of a new aminodiphosphonate (aminohydroxybutylidene diphosphonate) in patients with osteolytic lesions from metastases and myelomatosis. Comparison with dichloromethylene diphosphonate.
Attardo-Parrinello G; Merlini G; Pavesi F; Crema F; Fiorentini ML; Ascari E
Arch Intern Med; 1987 Sep; 147(9):1629-33. PubMed ID: 2957971
[TBL] [Abstract][Full Text] [Related]
18. Prostate cancer and bone metastases. The effect of clodronate.
Kylmälä T
Ann Chir Gynaecol; 1998; 87(1):59-60. PubMed ID: 9598233
[No Abstract] [Full Text] [Related]
19. Clodronate in the management of bone metastases: a clinical study of 91 patients.
Serkies K; Jereczek-Fossa B; Badzio A; Jassem J
Neoplasma; 1999; 46(5):317-22. PubMed ID: 10665850
[TBL] [Abstract][Full Text] [Related]
20. Dichloromethylene diphosphonate action in hematologic and other malignancies.
Canfield RE; Siris ES; Jacobs TP
Bone; 1987; 8 Suppl 1():S57-62. PubMed ID: 2961356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
